Persistent altered mental status without clear tox explanation
Focal neurologic deficit
Suspected posterior circulation stroke with nondiagnostic CT
Seizure with persistent deficit
MRI constraints
Unstable airway or ventilation
Need for continuous monitoring compatibility
CT
CT head indications
Head trauma or unwitnessed fall
Anticoagulant use
Persistent coma beyond expected drug kinetics
Focal neurologic findings
CT chest indications
Aspiration pneumonitis pneumonia concern
Unexplained hypoxemia
Ultrasound
Point of care ultrasound uses
Lung ultrasound for aspiration or pulmonary edema concern
B lines pattern
Consolidation pattern
Cardiac ultrasound for shock concern
Gross LV function
Pericardial effusion
IVC assessment adjunct in hypotension
Volume responsiveness adjunct only
Disposition
Level of care decisions
ICU indications
Ongoing ventilatory support
Recurrent apnea
Persistent hypercapnia despite support
Hemodynamic instability
Refractory hypothermia
Ward or monitored bed indications
Moderate sedation requiring prolonged observation
Long acting ingestion with delayed peak concern
Aspiration pneumonitis requiring oxygen
ED observation indications
Stable vital signs
Improving mental status trend
No coingestant red flags
Discharge criteria
Safe discharge criteria
Awake and oriented at baseline
Ambulation at baseline
Tolerating oral intake
Normal ventilation without supplemental oxygen
No delayed effect concern based on agent and time
Reliable supervision and follow up
Consultation and transfer
Consultation triggers
Poison center or clinical toxicology consult
Mixed ingestion concern
Flumazenil consideration
Barbiturate concern
Critical care consult
Airway support need
Vasopressor requirement
Psychiatry consult when indicated by clinical context
Safety assessment and disposition planning
Treatment
Supportive care
Core supportive treatment
Airway positioning
Lateral recovery position for vomiting risk
Suction setup
Oxygen and ventilation support
Nasal cannula for mild hypoxemia
Noninvasive ventilation for hypercapnia with intact airway reflexes
Intubation for apnea or inability to protect airway
Fluids and hemodynamics
Isotonic crystalloid bolus
Norepinephrine infusion for shock
Start low dose per local protocol
Titrate to MAP target
Central access if escalating dose
Temperature management
Active warming for hypothermia
Warmed IV fluids if moderate to severe hypothermia
Decontamination
Gastrointestinal decontamination
Activated charcoal considerations
Within 1 hour for substantial ingestion with protected airway
Avoid if altered mental status without protected airway
Avoid if imminent intubation not planned
Whole bowel irrigation
Rare role
Consider only for massive sustained release coingestion with toxicology guidance
Antidotes and reversal agents
Flumazenil
Indications
Iatrogenic benzodiazepine sedation with clinically significant respiratory depression
Known isolated benzodiazepine ingestion with high confidence
Contraindications
Chronic benzodiazepine use or dependence
Seizure disorder
Mixed ingestion with proconvulsants
Tricyclic antidepressant exposure concern
Adult dosing
Initiate 0.2 mg IV over 15 seconds
Repeat 0.2 mg IV every 1 minute if needed
Maximum 1 mg total for initial reversal attempt
Pediatrics dosing
Initiate 0.01 mg/kg IV
Maximum 0.2 mg per dose
Repeat every 1 minute if needed
Maximum 0.05 mg/kg or 1 mg total
Post reversal monitoring
Resedation risk
Observation length based on agent half life
Repeat dosing requirement evaluation
Seizure readiness
Immediate seizure management plan
Naloxone for suspected opioid coingestion
Trial dosing
Low dose IV titration for ventilation improvement
Escalate dosing if no response and high suspicion
Monitoring after response
Renarcotization risk with long acting opioids
Seizure and agitation management
Seizure management
Benzodiazepine first line for active seizures
Lorazepam IV dosing per local protocol
Midazolam IM or IN if no IV access
Second line agents
Levetiracetam dosing per local protocol
Valproate avoidance in pregnancy when possible
Refractory status epilepticus
Intubation with continuous infusion sedatives per ICU protocol
Agitation paradoxical reaction
Nonpharmacologic deescalation
Antipsychotic use with QT monitoring when needed
Barbiturate specific pathway
Barbiturate toxicity pathway
Alkalinization for phenobarbital with toxicology guidance
Sodium bicarbonate infusion
Titrate urine pH target per protocol
Potassium repletion to enable alkalinization
Extracorporeal removal consideration
Hemodialysis for severe phenobarbital with shock or coma
Toxicology consult for thresholds
Monitoring during treatment
Reassessment cadence
Frequent respiratory reassessment
Capnography trend
VBG repeat if worsening ventilation
Aspiration monitoring
Lung exam trend
Imaging if hypoxemia or fever develops
Special Populations
Pregnancy
Pregnancy considerations
Maternal resuscitation priority
Oxygenation and ventilation optimization
Left lateral uterine displacement if late pregnancy
Medication safety
Flumazenil use only with strong indication and toxicology input
Avoid valproate for seizures when alternatives available
Fetal considerations
Continuous fetal monitoring when viable gestational age and maternal instability
Obstetrics consult for significant overdose
Geriatric
Geriatric considerations
Increased sensitivity
Lower doses causing deeper sedation
Higher fall risk
Delayed clearance
Hepatic metabolism reduction
Drug accumulation with long acting agents
Disposition bias toward observation
Baseline cognitive impairment confounding
Higher aspiration risk
Pediatrics
Pediatric considerations
Small ingestion risk
Single tablet potentially significant in toddlers
Paradoxical agitation
Disinhibition
Need for safe environment and monitoring
Weight based dosing
Flumazenil dosing by kg when indicated
Airway equipment sizing readiness
Safeguarding context
Unsupervised access evaluation
Social work involvement when needed
Background
Epidemiology
Epidemiology
Benzodiazepines common contributor to polysubstance sedation presentations
Severe outcomes more likely with coingestants
Alcohol
Opioids
Older adults higher risk of falls and delirium with benzodiazepines
Pathophysiology
Pathophysiology
Benzodiazepines
Positive allosteric modulation of GABA A receptor
Increased chloride conductance
Enhanced inhibitory neurotransmission
Z drugs
GABA A receptor effects with relative selectivity
Similar sedation and amnesia profile
Barbiturates
GABA A receptor agonism
Greater respiratory depression risk than benzodiazepines
Additive depression with other CNS depressants
Synergistic respiratory depression with opioids and alcohol
Therapeutic Considerations
Treatment principles
Supportive care as mainstay for isolated benzodiazepine exposure
Airway and ventilation support prevents morbidity
Flumazenil risk benefit balance
Reversal benefit in select iatrogenic cases
Seizure and withdrawal risk in dependence or mixed ingestion
Decontamination limited by airway risk
Activated charcoal only with protected airway
Observation duration based on pharmacokinetics
Longer for long acting agents
Longer with hepatic impairment
Guideline posture and evidence labels
ACEP style evidence labeling
Routine flumazenil avoidance in undifferentiated overdose aligns with ACEP Level C consensus
Airway and ventilation support aligns with Class I resuscitation principles
Activated charcoal only with protected airway aligns with Class IIb toxicology consensus
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
Diagnosis explanation
Sedative medication exposure with slowed thinking and breathing risk
Next 24 hours safety
No driving
No alcohol
No cannabis
No sedating medications unless prescribed and reviewed
Responsible adult observation if available
Hydration and nutrition
Fluids as tolerated
Light meals as tolerated
Return to ED now for
Trouble breathing
Blue lips or severe sleepiness
Repeated vomiting
Chest pain
Fever or worsening cough
Confusion that worsens
Fainting or new weakness
Seizure
Follow up
Primary care within 1 to 3 days
Medication review for sedatives and interactions
Prevention
Keep medications locked and out of reach
Avoid mixing sedatives with alcohol or opioids
References
Clinical guidelines and consensus
Core guidance sources
American College of Medical Toxicology position statements on antidote use and toxicology consultation
American Academy of Clinical Toxicology guidance on GI decontamination and activated charcoal
Resuscitation council ACLS guidance for airway and hemodynamic instability management
Evidence based sources
Key evidence base
Reviews on flumazenil adverse events and seizure risk in mixed ingestion and benzodiazepine dependence
Clinical toxicology textbooks on sedative hypnotic toxidromes and management
Emergency medicine toxicology chapters on benzodiazepine and barbiturate overdose evaluation
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.